Secondary prevention of recurrent stroke.
Hankey
Graeme J
GJ
Stroke Unit, Department of Neurology, Royal Perth Hospital, School of Medicine & Pharmacology, University of Western Australia, Perth, Australia. gjhankey@cyllene.uwa.edu.au
D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000077144:Clopidogrel; D048909:Diabetes Complications / Q000517:prevention & control; D004691:Endarterectomy / Q000379:methods*; D016894:Endarterectomy, Carotid / Q000379:methods*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006710:Homocysteine / Q000097:blood; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012306:Risk; D012307:Risk Factors; D055502:Secondary Prevention; D015607:Stents; D020521:Stroke / Q000473:pathology* / Q000517:prevention & control*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014803:Vitamin B Complex / Q000378:metabolism
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D006710:Homocysteine; D014803:Vitamin B Complex; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin